In the rapidly evolving landscape of healthcare, innovative solutions are emerging to address the complex challenges of accessibility, affordability, and personalized care. At the forefront of this transformation is Inavya Ventures, a pioneering company harnessing the power of artificial intelligence (AI) to revolutionize the future of healthcare. Co-Founded by Michael Wilkinson, Inavya Ventures is driven by a singular mission: to democratize access to precision medicine and transform the lives of patients worldwide. Through its cutting-edge Avatr platform, strategic partnerships, and commitment to data-driven innovation, Inavya Ventures is poised to leave an indelible mark on the healthcare industry.

Join us for an impactful conversation as we delve into the transformative power of AI in healthcare with Michael Wilkinson, CEO of Inavya Ventures, a visionary leader at the forefront of revolutionizing patient care.

1. What motivated you to found Inavya Ventures, and what problem or opportunity in the healthcare industry did you hope to address through your company?

My journey in healthcare began with clinical work in Chicago, followed by public health research in London. During this time, I observed a concerning trend: many patients, including my own brother, struggled to adhere to their care plans, leading to declining health, hospital readmissions, and escalating healthcare costs. Conversely, another brother thrived due to his resilience intelligence and agency. This disparity sparked a question within me: could technology be harnessed to enhance resilience capabilities in patients?

This challenge became the catalyst for founding Inavya in London in 2015 with Aleardo Furlani. Leveraging our international experience, networks, and expertise in AI, healthcare, and innovation, we secured our first R&D grant in 2015, supported by the UK government and Deepbridge Capital. This grant enabled the development of the “Avatr” platform, inspired by Sanskrit philosophical principles.

Avatr is a mobile app that empowers users by providing personalized healthcare through data-driven insights and advanced AI tools. Recognizing the need to connect data, technology, and insights to manage chronic diseases – which account for approximately 80% of global healthcare costs – we developed Avatr to address this gap. Clinicians and researchers sought our expertise to optimize outpatient care using teams of synthetic experts.

In collaboration with Microsoft, we introduced Agentic Retrieval-Augmented Generation (RAG), enhancing human teams’ capabilities through Avatr Experts-as-a-Service. Inavya’s innovation orchestrates Semantic, Knowledge Graph, Machine Learning, and Agentic RAG technologies to streamline processes, improve decision-making, and transform the future of healthcare.

2. What are your thoughts on the recent collaboration between Inavya and HealthSum, and how do you perceive this collaboration will change the healthcare industry?

I firmly believe that our partnership with HealthSum is a game-changer for transforming healthcare in underserved areas. By integrating Inavya’s Avatr AI platform with HealthSum’s decentralized Electronic Health Record (EHR) and Micro Cloud, we’re pioneering a new approach that democratizes healthcare access, scales precision medicine, enhances sustainability, and fosters innovation in clinical research.

Key benefits of this collaboration include:

• Improved Uptime: HealthSum’s Micro Cloud keeps critical applications operational during network disruptions.
• Optimized Resource Use: Local data processing reduces bandwidth dependency and central server load, syncing only essential data.
• Enhanced Security: Local processing minimizes the risk of exposing sensitive patient information, increasing privacy.

Dr Michael John Wilkinson,
Co-Founder & CEO of Inavya Ventures ltd

3. How does Inavya’s Avatr technology integrate with HealthSum’s distributed ledger-based Electronic Health Record (EHR) system, and how does the Micro Clouds architecture support this integration?

This collaboration merges Avatr’s AI-driven self-management tools with HealthSum’s distributed ledger technology.

Front-end: Avatr

Avatr empowers patients to create, own and manage their AI-enabled digital profiles. This personalized approach is provided conveniently via WhatsApp, offering secure multimodal support across devices throughout their healthcare journey. Secure APIs enable efficient data exchange with HealthSum’s backend, ensuring a seamless user experience.

Back-end: HealthSum

Micro Kubernetes (mk8s) offers cloud-like functionality to local nodes, enabling compute-intensive tasks and resilience against failures. This open-source technology enhances scalability by dynamically allocating resources and maintaining operations during issues. By integrating mk8s, Micro Clouds bridge traditional cloud computing with edge deployments, ensuring robust performance in remote areas. Local data processing reduces bandwidth reliance, enhances patient data security, and provides clinicians timely access to insights.

4. How will the strategic partnership with the University of Oslo’s DHIS2 platform affect healthcare globally, and what specific advantages will likely emerge from it?

Inavya, HealthSum, and the University of Oslo are collaborating to integrate an AI-enabled patient portal into the DHIS2 platform, which is used in over 80 countries for health data management. HealthSum’s Micro Cloud architecture allows local health systems to function even with limited connectivity, improving real-time data access and analytics. Key advantages include:

• Improved Data Integration: The partnership facilitates seamless data flow between patient-level insights and aggregated health metrics, strengthening health program monitoring and evaluation.
• Capacity Building: By integrating HealthSum’s scalable Micro Cloud infrastructure, the partnership supports training and healthcare service delivery in low—and middle-income countries (LMICs), expanding local expertise and resources.
• Informed Public Health Responses: Combining DHIS2’s analytics with HealthSum’s real-time capabilities enables targeted interventions for disease outbreaks, better resource allocation, and informed policy-making.

5. Explain how Inavya’s technology could integrate with other emerging healthcare solutions, such as telemedicine and wearable devices.

Inavya’s Avatr platform integrates with wearables and hospital healthcare record systems, providing significant real-world capability to improve personalized healthcare services at scale.

Enhancement: Avatr enhances its capabilities by integrating wearables like fitness trackers and glucose monitors, enabling continuous data collection and real-time health monitoring. Predictive analytics can identify abnormalities, such as irregular heart rhythms, facilitating timely interventions. Including emerging lab test data—like radiography, blood analyses, and DNA sequencing—boosts Avatr’s precision medicine capabilities. This diverse data refines algorithms, resulting in more accurate diagnoses and tailored treatment plans, ultimately enhancing patient outcomes across various medical specialities.

Transformation: Innovations such as remote robotic surgeries and AI diagnostics are emerging. Inavya’s platform can be a central hub for presenting data from these sources, further advancing personalized, data-driven healthcare and reinforcing its role in a future healthcare landscape. Additionally, Avatr is poised to enhance the capabilities of robots serving as home healthcare assistants, connecting them to next-generation telemedicine services.

6. What are the advantages for patients and healthcare providers of using Inavya’s technology to
address the problem of fragmented health data streams?

Avatr provides key benefits to patients, clinicians, and researchers through data flows in a connected health ecosystem.

Patients: Avatr provides a valuable solution by offering a private synthetic healthcare assistant that helps patients manage their care plans. It consolidates data from prescribed care plans, wearable devices, and environmental information. Avatr delivers real-time insights and personalized recommendations for chronic conditions such as diabetes and cardiovascular disease. By empowering patients with actionable measures, Avatr encourages ownership of their health, thereby reducing frustration and feelings of helplessness during their healthcare journey.

Clinicians: Avatr improves decision-making by providing a unified, real-time view of a patient’s health status in various real-world situations, including at home, work, in the community, or while on the go. By integrating data from multiple sources, clinicians can effectively identify patterns, predict risks, and customize interventions. This approach enhances the accuracy of diagnoses and treatments. Additionally, the platform streamlines workflows, reduces administrative burdens and frees healthcare professionals to spend more time on patient care.

Researchers: Avatr provides direct access to various patient groups, allowing for diverse real-world data and evidence collection. This capability helps streamline workflows and improve the quality of research. One model that Inavya-HealthSum is exploring to strengthen local health ecosystems involves offering individuals health insurance in exchange for their participation in clinical studies.

7. How will the combined experience of Inavya and HealthSum enable more widespread access to personalized, precision medicine?

Inavya and HealthSum have partnered to advance personalized healthcare by integrating Inavya’s Avatr platform with HealthSum’s secure backend. This collaboration allows for tailored healthcare delivery, even in areas with poor connectivity, through HealthSum’s Micro Cloud architecture and distributed ledger technology for data security. It also introduces AI-curated micro health insurance for real-time adjustments based on patient needs, promoting affordability and accessibility. Healthcare providers gain actionable insights for personalized care, empowering patients to manage their health effectively and enhancing trust in AI-driven solutions.

8. Discuss how Inavya’s technology could be used in low and middle-income countries with limited healthcare resources.

In low—and middle-income countries, Inavya and HealthSum have formed a partnership to address healthcare challenges through innovative solutions. HealthSum’s Micro Cloud infrastructure allows for local data processing, reducing reliance on centralized systems and minimizing connectivity issues. Alongside Avatr’s AI capabilities, this empowers community health workers with real-time tools for monitoring and treatment.
The partnership promotes inclusivity via remote monitoring, predictive analytics, and virtual consultations, reducing the need for travel and prioritizing high-risk patients. By digitizing health information, Inavya and HealthSum enhance resilience in resource-limited settings and advance global health equity.

9. What makes Inavya unique, and how does its approach to data-driven healthcare differ from that of other businesses in the sector?

Inavya sets itself apart in the healthcare sector in several ways:

Agency: Avatr is designed to encourage patient agency. The toolset enables users to create, manage, and share their digital profiles. This is achieved by Avatr simulating resilience intelligence – perceiving, analyzing, and understanding multifactorial information and then providing highly personalised and contextualised actionable insight for each patient to consider. Avatr match-making algorithms provide patients with supply-side options that best match their demand requirements.

Experts-as-a-Service: Under the direct control of human clinicians and scientists, Inavya’s Agentic RAG technology can launch teams of synthetic experts to augment clinical and research teams, helping to streamline workflow.

Team: Inavya benefits from board members and other specialists with extensive international experience, including Co-Founder Aleardo Furlani (innovation and entrepreneurism), Jack Tsang (technology and investment lawyer), Dr Andrew Round (investment), Thomas Szczepaniak (investment), Dr Jaspal Sahota (AI Lead), Dr Alessio Gugliotta (AI), Dr Marko Vujasinovic (AI), Edoardo Gazzella (front-end developer), and Dr Benedict Babu (medical technologies). HealthSum experts bolster this capability with a diverse, experienced team covering clinical, technical, and operational expertise.

“ Inavya envisions a future where AI research is integrated into clinical practice through its Avatr AI platform, enhancing workflow efficiency and reducing costs. This platform promotes collaboration between AI and clinicians, allowing for better insights into complex case management. Inavya is committed to ensuring that AI enhances the human aspect of medicine by promoting responsible usage, addressing risks like inaccuracies and biases, and facilitating AI adoption in patient care.”

Aleardo Furlani
Co-Founder of Inavya Ventures Ltd

10. How will AI likely impact healthcare in the future, and how might Inavya benefit from these advancements?

Inavya’s focus on AI positions it as a leader in transforming healthcare. By offering personalized care pathways, real-time insights, flexible micro health insurance plans, and optimized health systems, Inavya aims to improve health outcomes and enhance access globally. It is well-positioned to contribute to and benefit from key developments in healthcare artificial intelligence.

Personalization: AI technology is poised to enhance disease prevention, accelerate drug discovery, and create personalized care pathways. Inavya’s Avatr platform leverages these advancements by integrating diverse health data for real-time insights using Agentic RAG technology. This allows Inavya to provide tailored care solutions for patients and clinicians. Additionally, AI enables Inavya to develop flexible, real-time micro health insurance plans tailored to individual patients’ health needs and financial situations.

Optimisation: Inavya improves clinical trial design and chronic disease management through collaboration with clinicians and researchers, utilizing Distributed Ledger Technology (DLT) and Micro Cloud architecture for secure data exchange and predictive analytics.

11. Provide case studies or success stories demonstrating how Inavya’s technology improves health outcomes.

Inavya has developed its Avatr technology in collaboration with leading teaching hospitals globally, tailoring its AI for specific needs and scalability. This has led to measurable improvements in clinical outcomes, economic efficiency, and quality of life, while also protecting and leveraging novel AI healthcare intellectual property.

In collaboration with Detecta Clinica in Lima, Avatr integrated AI-driven tools for post-surgery breast cancer patients, enhancing their care management. Additionally, Inavya developed its first synthetic expert – a Healthcare Assistant – to support patients in remote areas.

In partnership with Barts Health NHS, Avatr was adapted for South Asian cardiac patients in East London, addressing cultural needs to boost rehabilitation participation. Brazilian hospitals like InCor and The Cancer Institute have also utilized Inava to enhance cardiac and oncology care by leveraging various health data for better patient management and fewer readmissions. Inavya’s second synthetic expert, a Health Economist, was created at Imperial College Healthcare to automate health impact assessments. Later, it expanded to assist pharmaceutical companies with their R&D workflows.

“In collaboration with Inavya, InCor integrates the Avatr App, a mobile platform for managing chronic cardiac patients, particularly those with hypertension. The app enables personalized care through real-time monitoring and tailored recommendations. Telemonitoring fosters patient engagement, allowing healthcare teams to track progress and adjust care plans remotely. Tools like Avatr enhance treatment adherence, help identify complications early, and improve outcomes, highlighting the importance of digital solutions in patient-centered healthcare.”

– Guilherme Rabello
Head of Innovation, Instituto do Coração HCFMUSP, Sao Paulo BRAZIL

“Detecta Clínica, in collaboration with Inavya and supported by the British Embassy in Lima, piloted the Avatr App in Peru to assist breast cancer patients. With roughly 500 oncology surgeons for 34 million people, many patients travel to Lima for treatment—40% of ours come from remote highlands and forests. The pilot demonstrated Avatr’s effectiveness in supporting patients and reducing physicians’ workloads. We are now expanding Avatr to monitor chronic and common cancers in cities outside Lima, showcasing AI-driven solutions for accessible, patient-centered care.”

– Dr Claudia A. Sedano
Chief of Research & Development, Detecta Clínica, Lima PERU

What’s Changed for Startups?

A new type of agile startup is emerging as a potential market leader in today’s business landscape. Unlike traditional startups that depend on large venture capital, these challenger startups are lean and quick to seize market opportunities. They use emerging AI technologies to develop specialized, high-value products and services.

Inavya exemplifies this approach with its distributed team of experts, partnerships with Microsoft and HealthSum, and focus on Agentic RAG intellectual property. The company aims to become a key player in the growing AI healthcare market, which is projected to surpass $200 billion by 2028. To this end, Inavya will launch an 18-month global commercial implementation initiative in early 2025, during which it will validate commercial models and outline strategies for profitable scaling.

12. Looking ahead five to ten years, what will be Inavya’s most significant impact on the healthcare industry, and what steps is Inavya taking to realize this vision?

As noted below, Inavya aims to play a leadership role in the future of global healthcare. This will be achieved through focused efforts.

Accessibility: Inavya addresses key healthcare challenges, such as data fragmentation and inequitable access, by redefining healthcare delivery and management. It aims to democratize healthcare by making precision medicine accessible at the patient level in low-resource settings through AI, scalable infrastructure, and business model innovation. Collaborating with HealthSum will help Inavya expand its global solutions for underserved populations.

Experts-as-a-Service: Inavya plans to transform chronic disease management by deploying its Agentic RAG Experts-as-a-Service technology to enhance care, reduce hospital admissions, and improve health outcomes. Predictive analytics will shift healthcare towards more tuned and responsive services to meet an individual’s specific needs in time and place. In clinical research, Inavya’s Experts-as-a-Service will reduce the costs and time of clinical trials through process automation, improved recruitment, and synthetic control arms, ultimately accelerating treatment development. By unifying fragmented data streams, Inavya will create a data-driven ecosystem that advances drug discovery, manufacturing, and the delivery of personalized medicine.

13. Describe the main challenges concerning patient privacy, data security, and regulatory compliance in digital healthcare, and how Inavya manage these challenges.

Inavya addresses patient privacy, data security, and regulatory compliance challenges in digital healthcare by implementing advanced encryption protocols, strict access controls, and regular security audits. The company ensures adherence to regulations like HIPAA and GDPR through continuous employee training and policy updates.

Leveraging HealthSums’ Micro Cloud architecture, Inavya achieves scalable, flexible, and secure deployment of healthcare applications, enhancing interoperability and minimizing breach risks. Additionally, by integrating distributed ledger technology, Inavya ensures data integrity, transparency, and patient empowerment, providing immutable records and comprehensive audit trails.

This multifaceted approach fosters trust among patients and healthcare providers, leading to improved healthcare outcomes.

Dr Fredrick Lindberg (CEO) and Nigel Green (COO) of HealthSum Holding AS

14. As the CEO of Inavya Ventures, Michael Wilkinson, what leadership principle or approach do you believe has had the biggest impact on the company’s growth and innovation? How do you foster an innovative culture among your employees?

Innovation is a contact sport – CEOs need to be engaged on the playing field, learning from both failure and success, striving for continuous improvement. Innovation won’t happen by acting like an armchair quarterback, sitting on the bleachers, and not taking risks to win.

As a leader, my approach is shaped by decades of experience as a scientist, clinician and innovator. I provide an exceptionally intelligent and creative team the time, space, and resources that they need to deliver our shared vision. My background as an All-America track-and-field athlete from Wisconsin taught me the value of teamwork, perseverance, and a growth mindset. These principles drive transformational value for Inavya and our clients.

With a deep understanding of the healthcare market, I guide our team in adopting a demand-driven approach to innovation development. My focus is on ensuring that our Avatr technology delivers measurable clinical, economic, and quality-of-life benefits for our clients worldwide.

At the heart of our philosophy is a patient-first approach, which has led us to develop novel Agentic RAG technologies to redefine healthcare delivery, with Avatr Agents poised to support over 3 billion WhatsApp
users worldwide, sold via Microsoft Marketplace.

Company Name: Inavya ventures Ltd
Website: www.avatr.ai
Co-Founder & CEO: Michael Wilkinson